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ABSTRACT
Traditionally recognized as an RNA splicing regula-
tor, heterogeneous nuclear ribonucleoprotein C1/C2
(hnRNPC1/C2) can also bind to double-stranded
DNA and function in trans as a vitamin D re-
sponse element (VDRE)-binding protein. As such,
hnRNPC1/C2 may couple transcription induced by
the active form of vitamin D, 1,25-dihydroxyvitamin
D (1,25(OH)2D) with subsequent RNA splicing. In
MG63 osteoblastic cells, increased expression of the
1,25(OH)2D target gene CYP24A1 involved immuno-
precipitation of hnRNPC1/C2 with CYP24A1 chro-
matin and RNA. Knockdown of hnRNPC1/C2 sup-
pressed expression of CYP24A1, but also increased
expression of an exon 10-skipped CYP24A1 splice
variant; in a minigene model the latter was attenuated
by a functional VDRE in the CYP24A1 promoter. In
genome-wide analyses, knockdown of hnRNPC1/C2
resulted in 3500 differentially expressed genes
and 2232 differentially spliced genes, with signifi-
cant commonality between groups. 1,25(OH)2D in-
duced 324 differentially expressed genes, with 187
also observed following hnRNPC1/C2 knockdown,
and a further 168 unique to hnRNPC1/C2 knock-
down. However, 1,25(OH)2D induced only 10 differ-
entially spliced genes, with no overlap with differ-
entially expressed genes. These data indicate that
hnRNPC1/C2 binds to both DNA and RNA and influ-
ences both gene expression and RNA splicing, but
these actions do not appear to be linked through
1,25(OH)2D-mediated induction of transcription.
INTRODUCTION
Steroid hormones regulate gene transcription via nuclear
receptors (NR) that bind to specific DNA response ele-
ments around andwithin target genes. Transcriptional regu-
lation by NRs involves recruitment of coregulator proteins
that coordinate interactions with the basic transcriptional
machinery (1). NR coregulatory proteins have structural
similarities to RNA splicing proteins, suggesting that some
of these coregulators could act as coupling factors linking
transcription and RNA splicing (2). This dual role for NR
and their coregulators appears to be part of the process that
maintains both the magnitude and correctness of the gene
products generated in response to steroid hormone signals
(3). Given the importance of this facet of gene expression, a
reciprocal arrangement by which components of the splic-
ingmachinery act asNR transcriptional coregulators seems
likely.
A link between RNA splicing and the regulation of tran-
scription has been described for the stable small nuclear ri-
bonucleoproteins that make up the core of the spliceosome
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(4,5) and the splicing factors that facilitate formation of
the spliceosome and RNA splicing itself (6,7). Prominent
amongst this latter group is the heterogeneous nuclear ri-
bonucleoprotein (hnRNP) family of RNPs that associate
with pre-mRNA (heterogeneous nuclear RNA) and have
multiple functions in RNA processing (8). Owing to their
ability bind specifically to both single- (9–11) and double-
stranded (11–14) DNA elements, hnRNPs may also regu-
late the products of transcription by alternative means (15).
In previous studies we have shown that hnRNPs can modu-
late transcriptional responses to the active form of vitamin
D, 1,25-dihydroxyvitamin D (1,25(OH)2D), by competing
with the nuclear vitamin D receptor (VDR) for binding to
a vitamin D response elements (VDRE) that control tar-
get gene expression (16). Studies using cells from subhu-
man primates with a physiologically relevant state of rel-
ative insensitivity to the actions of 1,25(OH)2D (17) iden-
tified an hnRNP-like VDRE-binding protein (VDRE-BP)
(18,19) that attenuated 1,25(OH)2D-mediated transcription
by direct competition with the 1,25(OH)2D-activated VDR
for a VDRE (18).
Subsequent studies indicated that the human VDRE-BP
was hnRNPC1/C2 (20), with hnRNPC1/C2-induced vita-
min D-insensitivity postulated as a cause of hereditary vi-
tamin D resistant rickets (HVDRR) in a patient in the ab-
sence of a mutation in the VDR gene (19). In this partic-
ular case, dysregulation of 1,25(OH)2D-induced transcrip-
tion appears to be due to disruption of the normal cycli-
cal patterns of VDRE occupancy by direct competition
between VDR and hnRNPC1/C2 for DNA binding (20).
To date functional analysis of hnRNPC1/C2-VDR inter-
actions has focused on feedback suppression of expression
of the CYP24A1, the gene encoding the 24-hydroxylase en-
zyme which promotes the catabolism of 1,25(OH)2D (20).
CYP24A1 is known to be alternatively spliced, to gener-
ate in-frame mRNA variants that include skipping of ex-
ons 1 and 2 (CYP24A1-SV) (21), and exon 10 (CYP24A1
variant 2) (22). However, studies using cells from the HV-
DRR patient described previously suggest that the tran-
scriptional interaction between VDR and hnRNPC1/C2
involves many more genes (23). In the current study we
have utilized CYP24A1,as a model target gene in combi-
nation with genome wide analyses to assess the role of
hnRNPC1/C2 in coordinating transcriptional and RNA
splicing responses to 1,25(OH)2D.
MATERIALS AND METHODS
Reagents and cell culture
HumanMG63 osteosarcoma cells (American Type Culture
Collection, Manassas, VA, USA) were used as a model for
vitamin D signaling. Previous studies have shown that these
cells demonstrate vitamin D-induced gene expression re-
sponses common to normal human osteoblastic cells such
as osteocalcin and alkaline phosphatase (24,25). MG63
cells were cultured in Dulbecco’s modified Eagle medium
(Invitrogen) with 10% Fetal Bovine Serum at 37◦C with 5%
CO2. Crystalline 1,25-dihydroxyvitamin D3 (1,25(OH)2D3,
Enzo Life Sciences, Farmingdale, NY, USA) was reconsti-
tuted in ethanol. Ethanol (0.1%) was used as vehicle treat-
ment.
Analysis of 25OHD metabolism by MG63 cells
Activity of the 24-hydroxylase enzyme in MG63 cells
was quantified using tritiated 25-hydroxyvitamin D
(3H-25OHD, PerkinElmer, Waltham, MA, USA) sub-
strate as described previously (26). 3H-25OHD and
3H-24,25-dihydroxyvitamin D (3H-24,25(OH)2D) were
quantified using High Performance Liquid Chromatogra-
phy. Data were reported as fmoles of vitamin Dmetabolites
produced/hr/g cellular protein from n = 3 separate cell
preparations.
Western blot analysis
Cell lysates were prepared in RIPA buffer (150 mM sodium
chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulphate (SDS), 50 mM Tris, pH 8.0)
with 1x protease inhibitor cocktail (Thermo, Rockford, lL,
USA). Protein samples were separated by SDS-PAGE. An-
tibodies included: hnRNP C1/C2 (Santa Cruz Biotechnol-
ogy, # sc-32308); CYP24A1 (Santa Cruz Biotechnology, #
sc-32166); -actin (Santa Cruz Biotechnology, # sc-81178).
Quantitative RT-PCR (qRT-PCR) analyses
Total RNA was extracted from MG63 cells and reverse
transcribed using RNeasy mini kit (Qiagen, Valencia, CA,
USA) and SuperScript III Reverse Transcriptase (Invitro-
gen) as described previously (23). Polymerase chain reac-
tion (PCR) amplification of cDNA was carried out using
TaqMan system reagents (Applied Biosystems) as described
previously (23), under following conditions: (i) 95◦C for 10
min; 40 cycles of [95◦C for 15 s, 60◦C for 1 min] or (ii) 95◦C
for 10 min, 40 cycles of [95◦C for 15 s, 55◦C for 30 s, 72◦C
for 30 s] and then finally 72◦C for 2 min using Maxima
SYBR Green qPCRMaster Mixes (Thermo). Target genes
were normalized to 18S (Primers from Applied biosystems,
Carlsbad, CA, USA) or GAPDH expression. The primers
sequences used are described in the Supplementary Table
S1. All reactions were performed in triplicate for each bio-
logical experiment.
Chromatin immunoprecipitation-qPCR (ChIP-qPCR)
Chromatin immunoprecipitation (ChIP) was performed as
described previously (20) with several modifications. Briefly,
following treatment with 10 nM 1,25(OH)2D or vehicle for
3 h, cells were washed twice with phosphate-buffered saline
(PBS) and crosslinked with 1% formaldehyde at room tem-
perature for 10 min. After quenching of cross-linking with
glycine at final concentration of 125 mM, cell monolayers
were washed twice with cold PBS and then scraped into
5 ml cold PBS. Collected cells were pelleted by centrifu-
gation for 5 min at 1000 g and the resulting pellets re-
suspended in 1 ml of ChIP lysis buffer (5 mM Pipes, pH
8.0, 85 mM KCl, 0.5% Nonidet P-40, 1 mM dithiothreitol,
0.25 mM phenylmethylsulfonyl fluoride and 1 g/ml each of
pepstatin, leupeptin and aprotinin) with protease inhibitor
cocktail (Thermo). The resulting chromatin lysates were
sonicated to yield sheared DNA fragments of sizes between
300 and 1000 bp, and then centrifuged for 10 min, 8000 g at
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4◦C. Supernatants were removed and aliquots used as ‘In-
put’ sample. For each immunoprecipitation, sheared chro-
matin was diluted 1:10 with ChIP dilution buffer (1%Triton
X-100, 2 mM EDTA, 150 mM NaCl and 16.7 mM Tris-
HCl, pH 8.1) with 1x protease inhibitor cocktail (Thermo).
The chromatin was incubated at 4◦C overnight with 50 l
of magnetic Dynabeads protein A (Life Technologies AS,
Oslo, Norway) pre-conjugated with antibodies. The bead–
antibody–antigen complexes were then subjected to serial
washes of 10 min each with 2 × 1 ml ChIP-RIPA (1 mM
EDTA, 0.7% sodium deoxycholate, 1% NP-40, 0.5 M LiCl,
50 mM HEPES, pH 7.6), 2 × 1 ml ChIP-RIPA buffer and
2 × 1 ml TE buffer (1 mM Tris, pH 7.6, 1 mM EDTA).
The resulting immune complexes were then resuspended in
100 l reversal dilution buffer (1% SDS, 0.1 M NaHCO3),
and vortexed for 30 s every 5 min for 30 min. Formalde-
hyde cross-linking was reversed by heating at 70◦C 2 h.
DNA was extracted using QIAquick Gel Extraction Kit
(Qiagen) and analyzed by qRT-PCR. ChIP grade antibod-
ies against VDR (Santa Cruz Biotechnology, Santa Cruz,
CA,USA; sc-13133), hnRNPC1/2 (SantaCruz Biotechnol-
ogy, # sc-32308) were used. Normal mouse or rabbit IgG
(Santa Cruz Biotechnology, # sc-2025, sc-2027) was used
as the negative control. qRT-PCR was performed as de-
scribed above with primer set flanking enhancer VDREs
in the proximal CYP24A1 (VDRE1 [−150 bp] CGCCCT-
[CAC]TCACCT [−136 bp] and VDRE2 is [−258 bp] CG-
CACC[CGC]TGAACC [−244 bp]). Primers were designed
to amplify a region of DNA from −304 to −63 bp relative
to the start site of transcription (Supplementary Table S1).
A separate primer set spanning a region not harboring a
VDRE in calponin 1 (CNN1) was used as a negative con-
trol (Supplementary Table S1). The amplified products were
normalized to InputDNA content and presented as percent
of Input. ChIP experiments were performed in three biolog-
ical independent replicates.
RNA immunoprecipitation (RIP) from cell lysates
RNA immunoprecipitation (RIP) was performed using
MILLIPORE Magna RIP™ RNA-Binding Protein Im-
munoprecipitation Kit (Millipore, # 17–700) according to
manufacturer’s instructions. Antibodies to hnRNPC1/C2
(Santa Cruz Biotechnology, # sc-32308), VDR (Santa Cruz
Biotechnology, # sc-13133), normal mouse or rabbit IgG
(Santa Cruz Biotechnology, # sc-2025, sc-2027) were used.
Anti-SNRNP70 (Millipore, Temecula, CA, USA) was a
positive control antibody. RNA extraction and qPCR were
as described above.
Small interfering RNA (siRNA) knockdown of
hnRNPC1/C2
Two different human hnRNPC1/C2 stealth select small
interfering RNA (siRNA) (Invitrogen, HSS179304 and
HSS17930) and a stealth siRNA negative control low GC
(Invitrogen) were used. Knockdown of hnRNPC1/C2 was
performed as described previously (27). Briefly, MG63 cells
were plated at 105 cells/well in a 6-well cluster plate in 2 ml
growth medium and 0.03 × 106 cells/well in a 24-well plate
in 0.5 ml of growth medium. Cells were transfected at 20–
30% confluency with hnRNPC or control siRNA at a final
concentration of 5 nM, using Lipofectamine RNAiMAX
(Invitrogen) transfection reagent according to the manufac-
turer’s protocol. Ninety six hours after transfection, cells
were harvested and knockdown efficiency assessed by qRT-
PCR and Western blot. All transfection experiments were
performed in triplicate. Transfection efficiency of siRNAs in
MG63 cells was determined by using Block-iT Alexa Fluor
Red Fluorescent Control Oligo (Invitrogen, cat# 14750-
100). Optimization of siRNAknockdown of hnRNPC1/C2
is shown in Supplementary Figure S1.
Fluorescently labeled PCR
Fluorescently labeled PCR to visualize endogenous, al-
ternatively spliced CYP24A1 exon 10 products was mod-
ified from previously described methods (28). Briefly,
a 22 nt universal tag sequence (designated ‘GFPN’),
5′-CGTCGCCGTCCAGCTCGACCAG-3′ derived from
GFP N-terminal region, was added to the 5′ end of the
forward primer during oligo synthesis, while the reverse
primer remained untagged. A fluorescently labeled univer-
sal primer 5′-FAM-CGTCGCCGTCCAGCTCGACCAG-
3′ was added as a third primer in the PCR reaction, un-
der the following amplification conditions: (i) 98◦C for 10
s, 32 cycles of [98◦C for 30 s, 50◦C for 30 s, 72◦C for 1 min]
and then (ii) 72◦C for an additional 10 min. Primer sets
are shown in Supplementary Table S1. Reaction products
were resolved on 5% TBE-urea polyacrylamide gels and vi-
sualized using a BIO-RAD ChemiDocTM MP Gel Imaging
system (Bio-Rad, 170–8280). Bands were quantified using
Image lab software (Bio-Rad). Exon inclusion levels were
calculated as the intensity of the exon inclusion band di-
vided by the total intensity of the exon inclusion and skip-
ping bands.
Analysis of alternative RNA splicing using CYP24A1 mini-
gene constructs
CYP24A1 mini-gene splicing cassettes were cloned using
genomic DNA isolated from MG63 cells with the Qiagen
DNeasy kit. A DNA fragment containing the 3′ portion of
exon 9, intron 9, exon 10, intron 10 and the 5′ portion of
exon 11 of CYP24A1 was synthesized with Q5 Hot Start
High-Fidelity 2x master mix using a forward primer con-
taining Not I, 5′ ATATATGCGGCCGCGGCAACAGTT
CTGGGTGAAT 3′ and a reverse primer containing Apa
I 5′ ATATATGGGCCCATTGTCTGTGGCCTGGATGT
3′. A pcDNA 3.1(+) and PCR fragment was sequentially
digested with Not I and Apa I and purified with the Qia-
gen DNA gel extraction kit for isolation by agarose gel elec-
trophoresis. Ligation of DNA fragments was accomplished
withNEBT7 ligase, and library efficiencyDH5a competent
cells (Thermo) were transformed and screened.
Genomic DNA from MG63 was also used as template
to generate PCR fragments containing specific proximal
promoters with Q5 Hot Start High-Fidelity 2x master
mix. The PCR primer sets used to generate CYP24A1
(−1197/+87 bp), interleukin-6 (IL-6) (−1183/+31 bp),
β-actin (ACTB) (−472/+49 bp), Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH) (−487/+20) and
osteocalcin (BGLAP) (−834/+46 bp) gene fragments
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are shown in Supplementary Table S2. The CMV pro-
motor of pcDNA3.1(+) was removed by sequential
digestion with Nru I and Kpn I and replaced by lig-
ation of specific proximal promoters described above
with forward primers containing the Nru I site and re-
verse primers containing the Kpn I site. An additional
CYP24A1 promoter fragment was generated containing
mutations in the VDRE introduced using the Agilent
QuikChange Site-Directed Mutagenesis Kit with primers
designed via Agilent QuikChange primer design program
(http://www.genomics.agilent.com/primerDesignProgram.
jsp). VDRE-1: AGGTGAGCGAGGGCG (wild-
type), TCCTGAGCGTCCGCG (mutated).
VDRE-2: AGTTCACCGGGTGTG (wild-type),
TCCTCACCGTCCGTG (mutated). Half-sites are shown
in bold and underlined sequences show introduced
mutations (29).
For transfection of minigene constructs,MG63 cells were
cultured in 12-well plates and transfected at 30% confluency
with Lipofectamine 3000 (Invitrogen) according to man-
ufacturer protocols. Forty eight hours post-transfection,
RNA was isolated by Trizol followed by in-column DNAse
treatment according to Qiagen RNeasy protocol. cDNA
was prepared from 500 ng RNA by SuperScript III re-
verse transcriptase. Minigene splice products were gener-
ated by PCR using primer sets shown in Supplementary Ta-
ble S3 with Q5 Hot Start High-Fidelity 2x master mix us-
ing the following amplification conditions: 98◦C for 30 s;
25 to 36 cycles of 98◦C for 10 s, 60◦C for 20 s, 72◦C for 1
min. PCR products were analyzed by agarose electrophore-
sis with ethidium bromide; band intensity was determined
by ImageJ verision 1.49 and exon skipping percentage was
calculated.
High-throughput RNA sequencing (RNAseq) and genomic
mapping
RNA extracted was extracted from MG63 cells us-
ing RNAeasy mini kit (Qiagen, Valencia, CA, USA)
with on-column DNase treatment to remove genomic
DNA. cDNA libraries were prepared using the Illumina
TruSeq RNA Sample Preparation Kit (illumina). High-
throughput sequencing was performed using an Illumina
HiSeq2500 (paired-end, non-strand-specific 107-bp read
length). Knockdown and control samples were sequenced
together in two flow cells on four lanes. Reads from each
of four lanes were combined for all analyses. A total of 525
million 107-bp paired-end reads were generated by sequenc-
ing (Supplementary Table S4). Reads were mapped to hu-
man transcripts (Ensembl, release 72) and genome (hg19)
using Tophat software (v1.4.1) (30) allowing up to 3 bpmis-
matches per read and up to 2 bp mismatches per 25 bp
seed.More than 60% of all RNAseq readsmapped uniquely
to the human genome (Supplementary Table S4). RNAseq
data were deposited with the NCBI Gene Expression Om-
nibus <<GSE63086>>.
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
qtyzgcaifzkxvev&acc=GSE63086.
Analyses of differential gene expression/alternative splicing
Cuffdiff (v.2.2.0) (31) was used to calculate gene expression
levels with the FPKM metric (fragments per kilobase of
exon per million fragments mapped) and differential gene
expression (DEG) between two conditions assessed at an
false detection rate (FDR) < 1% and minFPKM > 0.1.
rMATS (v3.0.8)] (30–33) (http://rnaseq-mats.sourceforge.
net/) was used to identify differential alternative splicing
(AS) events corresponding to five major types of AS pat-
terns. AS events were identified as those with significant
difference in inclusion levels (|PSI| ≥ 0.05) between two
groups, FDR < 0.05. Stringency for AS events was defined
for varying PSI and compared with different stringency for
DEG (Supplementary Figure S2) to provide comparable
DEG and differentially splice genes for each cell condition.
RT-PCR validation of differentially spliced exons identified
by RNA-seq
RNA extraction, reverse transcription and PCR amplifica-
tion were as described previously (23). Sequences for primer
pairs used are listed in Supplementary Table S1.
Data normalization and statistical analysis
Data for ChIP-qPCR assays were reported as % input, and
normalized as described previously (23). Briefly, each ChIP
DNA fraction Ct value was normalized to the input DNA
fraction to account for chromatin preparation differences:
Ct[normalized ChIP] = {Ct[ChIP] - [Ct[input] - log2 (input dilution
factor)]}, where the dilution factor was 100. Triplicate nor-
malized ChIP Ct values were meaned. To calculate % In-
put for each ChIP fraction, linear conversion of normal-
ized ChIPCt: % Input= 2 (-Ct [normalized ChIP]. Data for RIP-
qPCR were presented and normalized as for ChIP-qPCR.
Data were compared statistically using an unpaired Stu-
dent’s t-test and one way analysis of variance (ANOVA)
with Tukey’s multiple-comparison post-hoc test as indi-
cated.
RESULTS
1,25(OH)2D-induced 24-hydroxylase activity is associated
with increased expression ofCYP24A1 andCYP24A1-splice
variants
MG63 cells treated with 1,25(OH)2D showed increased
24-hydroxylase activity (conversion of 3H-25OHD to
3H-24,25-dihydroxyvitamin D (3H-24,25(OH)2D); Figure
1A). This was associated with increased expression of
the full length CYP24A1-24-hydroxylase protein (Figure
1C). By contrast, 1,25(OH)2D had no effect on expres-
sion of mRNA (Figure 1B) or protein (Figure 1C) for
hnRNPC1/C2. Time course qRT-PCR analyses showed
that 1,25(OH)2D-induced 24-hydroxylase activity was as-
sociated with increased expression of full length mRNA
for CYP24A1 (Figure 1D) and two splice variants of
the CYP24A1 gene, CYP24A1-variant 2 (Figure 1E) and
CYP24A1-splice variant (CYP24A1-SV) (Figure 1F).
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Figure 1. Effect of 1,25(OH)2D on 24-hydroxylase and hnRNPC1/C2 inMG63 cells. (A) (Left) 24-hydroxylase enzyme activity (conversion of 3H-25OHD
to 3H-24,25(OH)2D) in MG63 cells 24 h after addition of vehicle or 1,25(OH)2D (10 nM). Data are mean ± SD fmol 3H-24,25(OH)2D/hr/g cell protein
(n = 3, **P< 0.01, Student’s t-test). (Right) Representative high performance liquid chromatography analyses for vehicle (top) and 1,25(OH)2D (bottom)
treatment. (B) qRT-PCR analysis of hnRNPC1/C2mRNA expression after treatment with vehicle or 1,25(OH)2D (10 nM) for 12 h. Data are mean ± SD,
n = 3. n.s., non-significant. (C) Western blot analysis of 24-hydroxylase and hnRNPC1/C2 with vehicle or 1,25(OH)2D (10nM) 12 h; N.T., No Treatment.
(D) Expression of mRNA for full lengthCYP24A1, E.CYP24A1-variant 2 (exon 10 skipped), F.CYP24A1-SV (exon 1 and 2 skipped) following treatment
with 1,25(OH)2D (10 nM) up to 12 h. Data are mean ± SD (n = 3, P < 0.05, 1-way ANOVA). Lower panels D and F show schematic illustrations of the
full-length, wild-type CYP24A1 and the exon organization of the splice variants described above.
hnRNPC1/C2 binds to DNA and pre-mRNA for CYP24A1
ChIP-qPCR analyses showed that in the absence of
1,25(OH)2D, there was low level binding of both VDR
and hnRNPC1/C2 to a region of the CYP24A1 gene pro-
moter (−304 to −63 bp upstream of the transcriptional
start site for CYP24A1) containing a VDRE (Figure 2A).
However, in contrast to hnRNPC1/C2, binding of VDR
to the CYP24A1 proximal promoter was increased fol-
lowing treatment with 1,25(OH)2D (Figure 2A). Parallel
RNA immunoprecipitation (RIP)-qPCR was carried out
using primers targeted at pre-mRNA, intronless mature
mRNA or both pre- and mature mRNA for CYP24A1
(Figure 2B–D). Pre-mRNA for CYP24A1 showed signif-
icantly higher binding of hnRNPC1/C2 following treat-
ment with 1,25(OH)2D. For the mature CYP24A1mRNA,
hnRNPC1/C2 showed low level association that was unaf-
fected by 1,25(OH)2D (Figure 2C). RIP with antibodies for
VDR showed no association of the receptor with pre- or
mature RNA for CYP24A1 (data not shown).
Effects of hnRNPC1/C2 knockdown on expression of
CYP24A1 and splice variants
To assess the functional impact of hnRNPC1/C2 on vi-
tamin D-mediated transcription and pre-mRNA splic-
ing, siRNA was used to knockdown hnRNPC1/C2 in
MG63 cells (Figure 3A). RT-PCR analyses showed diver-
gent effects of hnRNPC1/C2 knockdown on full length
CYP24A1 mRNA and splice variants (Figure 3B–D). In
vehicle-treated cells, CYP24A1 mRNA was decreased and
CYP24A1-variant 2 increased with hnRNPC1/C2 knock-
down (Figure 3B and C). Knockdown of hnRNPC1/C2
had no effect on CYP24A1 expression when performed in
conjunction with exposure to 1,25(OH)2D. Expression of
CYP24A1-variant 2 was induced by 1,25(OH)2D in a fash-
ion similar to that for full length CYP24A1, but this effect
was significantly enhanced with hnRNPC1/C2 knockdown
(Figure 3C); induction of CYP24A1-variant 2 was 62-fold
± 3, and 72± 8 in KD1 andKD2 cells versus 45± 3 in con-
trol cells. CYP24A1-SV was unaffected by hnRNPC1/C2
knockdown in either vehicle or 1,25(OH)2D-treated cells
(Figure 3D).
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Figure 2. CYP24A1 DNA and RNA binding of hnRNPC1/C2. (A) Chromatin immunoprecipitation (ChIP) using antibodies to hnRNPC1/C2 (C1/C2)
or vitamin D receptor (VDR). Precipitated DNA was PCR amplified with primers to a VDRE-containing region of CYP24A1 promoter and a VDRE-
negative region of calponin 1 (CNN1) (negative control). Data are % of input DNA. (B–D) RNA immunoprecipitation (RIP) analyses using antibodies to
hnRNPC1/C2 (IgG as a control). Precipitated RNA was PCR amplified with primers encompassing CYP24A1 pre-mRNA, mature CYP24A1 RNA or
both as indicated. Data are % of input RNA. Cells were treated with vehicle or 1,25(OH)2D (10 nM) for 3 h. Data are mean ± SD (n = 3, *P< 0.05, ***P
< 0.001, Student’s t-test, #, undetectable). n.s. = non-significant.
To further characterize generation of the CYP24A1-
variant 2 in MG63 cells, CYP24A1 exon 10-inclusion was
quantified using fluorescently tagged RT-PCR (Figure 3E).
Vehicle-treated cells showed 96.9% inclusion of exon 10,
which was reduced to 93.9% and 89.0% after knockdown
of hnRNPC1/C2. In 1,25(OH)2D-treated cells, inclusion
of exon 10 was similar to vehicle (97.8%). However, in
1,25(OH)2D-treated cells with hnRNPC1/C2 knockdown,
inclusion of exon 10 decreased to 73.7% and 75.7%. An al-
ternatively spliced product (lacking exon 10) was present in
each of the hnRNPC1/C2 knockdown treatments, but the
PCR band corresponding to this product was more pro-
nounced in 1,25(OH)2D-treated cells (Figure 3E).
VDRE expression and mRNA splicing in a CYP24A1 mini-
gene model
To assess a possible link between VDRE and mRNA splic-
ing for 1,25D-VDR-target genes, aCYP24A1mini-gene ex-
pression construct was used tomimic alternative splicing as-
sociated withCYP24A1-variant 2 (exons 9–11). In the pres-
ence of a conventional CMV promoter or other promoters
lacking a VDRE (IL-6, ACTB and GAPDH), exon skip-
ping to generate a transcript lacking exon 10 ranged from
15–22% of correctly spliced transcript (Figure 4). By con-
trast, minigene constructs containing functional VDRE(s)
(CYP24A1 andBGLAP) showed less exon 10 skipping (5.37
± 0.67% and 7.00 ± 1.91%, respectively). The enhanced
splicing fidelity associated with theCYP24A1 bearing func-
tional VDREs was diminished by mutation of specific nu-
cleotides associated with VDR-VDRE interaction (10.03±
2.50%).
Genome-wide analysis of the effects of hnRNPC1/C2 knock-
down on transcription and mRNA splicing
To define the genome-wide impact of hnRNPC1/C2 on
1,25(OH)2D-induced transcription and RNA splicing, high
throughput RNA-seq analysis of MG63 cells was car-
ried out. Knockdown of hnRNPC1/C2 resulted in 3500
differentially expressed genes relative to vehicle-treated
control cells (Supplementary Data S1), whilst treatment
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Figure 3. Effect of HnRNPC1/C2 knockdown on CYP24A1 transcription and pre-mRNA splicing. MG63 cells were transfected with two hnRNPC1/C2
siRNAs (KD1 andKD2) or scrambled control siRNA (Ctrl). (A) Western blot analysis of CYP24A1 24-hydroxylase and hnRNPC1/C2. Cells were treated
with vehicle or 1,25(OH)2D (10 nM) for 12 h. (B–D) qRT-PCR analysis of mRNA for: (B) wildtypeCYP24A1; (C)CYP24A1-variant 2; (D)CYP24A1-SV
in KD1, KD2 and Ctrl cells. (E) CYP24A1 exon 10 inclusion by fluorescently labeled RT-PCR. (Left) Inclusion (gray) and exclusion (white) of exon 10.
(Right) Gel visualization of PCR products with exon 10 inclusion or skipping. For D–G, cells were treated with vehicle or 1,25(OH)2D (10 nM) for 12 h.
Data are mean ± SD (n = 3, *P < 0.05, **P < 0.01, Student’s t-test).
Figure 4. Alternative splicing of CYP24A1 is modulated by VDRE. Splicing of minigene constructs transfected intoMG63 cells containingDNA for exons
9–11 of CYP24A1 linked to promoter DNA from: CMV; CYP24A1 containing two wild-type VDREs; CYP24A1 bearing mutated, non-VDR binding
VDREs; VDRE-negative IL-6, ACTB and GAPDH promoters; and VDRE-positive BGLAP. (A) Example of a gel showing bands for correctly spliced
minigene transcripts containing exons 9, 10 and 11 (upper band) and alternatively spliced transcripts containing only exons 9 and 11 (skipped exon 10,
lower band). (B) Percent exon 10 skipping for each minigene-promoter construct (mean ± S.D., n = 3 separate transfections). * = statistically different
from CYP24A1, P < 0.05. Constructs with functional VDRE are highlighted as boxes.
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with 1,25(OH)2D resulted in 324 differentially expressed
genes relative to vehicle control cells (Supplementary
Data S2), Comparing these two data sets, 153 differen-
tially expressed genes, including CYP24A1, were common
to hnRNPC1/C2 knockdown and 1,25(OH2D-treatment
(Figure 5A). Of the 171 differentially expressed genes spe-
cific to treatment with 1,25(OH)2D, 100 were also observed
when comparing hnRNPC1/C2 knockdown with com-
bined 1,25(OH)2D and hnRNPC1/C2 knockdown, whilst
a further 87 differentially expressed genes were only in-
duced by 1,25(OH)2D in hnRNPC1/C2 knockdown cells
(Figure 5A) (Supplementary Data S3). Cells with com-
bined hnRNPC1/C2 knockdown and 1,25(OH)2D treat-
ment also showed a high number of differentially expressed
genes (3844) relative to vehicle control cells (Supplemen-
tary Data S4). Of these, 2932 differentially expressed genes
(76.3%) were common to hnRNPC1/C2 knockdown alone,
with 912 being specific to treatment with 1,25(OH)2D in
combination with hnRNPC1/C2 knockdown (Figure 5B).
The distinct nature of these differentially expressed genes
is also illustrated by heatmap representation of the dif-
ferentially expressed genes within the various sectors of
the Venn diagram comparisons shown in Figure 5A. The
heatmap comparison for hnRNPC1/C2 knockdown ver-
sus 1,25(OH)2D and hnRNPC1/C2 knockdown (KD ver-
sus 1,25+KD) shows the strongest contrast between these
treatments (see Supplementary Figure S3).
Differentially expressed genes induced by knockdown
of hnRNPC1/C2 alone were 57% down-regulated (includ-
ing CYP24A1) and 43% up-regulated (Figure 5C). By
contrast, treatment with 1,25(OH)2D alone favored up-
regulation of gene expression (70% of differentially ex-
pressed genes) (Figure 5C). This included induction of
the CYP24A1 gene (Supplementary Figure S4), a response
that was also observed when comparing hnRNPC1/C2
knockdownwith the combination of hnRNPC1/C2 knock-
down and 1,25(OH)2D (Figure 5C). In total 322 genes
were upregulated following treatment with 1,25(OH)2D.
Of these, 25% (82) were induced by 1,25(OH)2D alone,
whilst 30% (95) were only induced by a combination
of 1,25(OH)2D treatment and hnRNPC1/C2 knockdown
(Figure 5D). The remaining 45% of genes (145/322) were
common to treatment with 1,25(OH)2D or 1,25(OH)2D
with hnRNPC1/C2 knockdown; importantly, this group
included CYP24A1 (Figure 5D). Of the 171 genes down-
regulated by 1,25(OH)2D, 33% (56) were only suppressed
by 1,25(OH)2D alone, while 43% (74) were only sup-
pressed by the combination of 1,25(OH)2D treatment with
hnRNPC1/C2 knockdown (Figure 5D); the remaining 24%
(41/171) were common to treatment with 1,25(OH)2D or
combination 1,25(OH)2D treatment with hnRNPC1/C2
knockdown (Figure 5D).
Alternative splicing was assessed using a statistical al-
gorithm for RNAseq, multivariate analysis of transcript
splicing (MATs) (32,34), that detects differentially spliced
genes corresponding to the five major modes of types of
AS described in metazoan organisms (Figure 6A and Sup-
plementary Data S5). Using this program, AS was ana-
lyzed following knockdown of hnRNPC1/C2, with or with-
out 1,25(OH)2D. In MG63 cells 3921 differentially spliced
genes (FDR < 0.05, |PSI| ≥ 0.05) were observed fol-
lowing hnRNPC1/C2 knockdown, with the majority of
these (2713) being skipped exons (Figure 6B). Differen-
tially spliced genes induced by hnRNPC1/C2 knockdown
in MG63 cells were compared with previously reported
differentially spliced genes in hnRNPC1/C2 knockdown
HeLa cells (27); 542 differential splicing events being com-
mon to MG63 and HeLa cells (Supplementary Figure S5).
RT-PCR confirmed differentially spliced genes following
hnRNPC1/C2 knockdown in 12 transcripts identified by
MATs (Supplementary Figure S6).
In the absence of hnRNPC1/C2 knockdown, compared
to vehicle alone-treated cells, treatment with 1,25(OH)2D
resulted in only 10 differentially spliced genes (FDR <
0.05, |PSI| ≥ 0.05) (Figure 6B). Relative to treatment with
1,25(OH)2D only, exposure to combined hnRNPC1/C2
knockdown and 1,25(OH)2D resulted in 4525 differentially
spliced genes (FDR< 0.05, |PSI| ≥ 0.05), with one of these
being exon 10 skipping inCYP24A1 to generateCYP24A1-
variant 2 (PSI: −0.103, Supplementary Figure S4); this
CYP24A1 alternative splicing was also observed when com-
paring hnRNPC1/C2 knockdown alone with 1,25(OH)2D-
treatment alone.
Exon skipping (including the skipped exon 10 of
CYP24A1) was far more evident when comparing cells
treated with 1,25(OH)2D in the presence of hnRNPC1/C2
knockdown versus 1,25(OH)2D alone (Figure 6). In this set-
ting, the dominant determinant of skipped exons contin-
ued to be hnRNPC1/C2 knockdown, with 2284 skipped
exons being common to 1,25(OH)2D versus 1,25(OH)2D
and hnRNPC1/C2 knockdown when compared to vehi-
cle control versus 1,25(OH)2D and hnRNPC1/C2 knock-
down (Supplementary Figure S7). However, this compar-
ison also showed that 889 skipped exon events (including
exon 10 skipping in CYP24A1) were only observed when
comparing 1,25(OH)2D with combined 1,25(OH)2D and
hnRNPC1/C2 knockdown (Supplementary Figure S7).
These data indicated that a discreet set of AS are as-
sociated with 1,25(OH)2D treatment in the presence of
hnRNPC1/C2 knockdown, with these events being distinct
from AS due to hnRNPC1/C2 knockdown alone.
Of the 3500 differentially expressed genes induced by
hnRNPC1/C2 knockdown (see Figure 5), 584 (16.7%)
were also shown to be differentially spliced genes (Fig-
ure 7A). By contrast none of the 324 differentially ex-
pressed genes induced by exposure to 1,25(OH)2D alone
were also differentially spliced under these conditions (Fig-
ure 7B), and only 1 of 3 differentially spliced genes induced
by hnRNPC1/C2 knockdown and 1,25(OH)2D treatment,
compared to hnRNPC1/C2 knockdown alone, was also
a differentially expressed gene (Figure 7C). When com-
pared to cells only receiving 1,25(OH)2D, cells receiv-
ing 1,25(OH)2D in the presence of hnRNPC1/2 knock-
down showed 3572 differentially expressed genes and 2510
differentially spliced genes, with 706 (19.8%/28.1%) be-
ing both differentially expressed and spliced (Figure 7D).
Comparison of vehicle-treated cells with those exposed to
1,25(OH)2D in combination with hnRNPC1/C2 knock-
down showed 3844 differentially expressed genes and 2535
differentially spliced genes, with 696 (18.1%/27.5%) being
both differentially expressed and spliced (Figure 7E).
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Figure 5. Differential gene expression by 1,25(OH)2D or hnRNPC1/2 knockdown. Weighted Venn diagrams depicting overlap of differentially expressed
genes: (A) Control versus hnRNPC1/C2 knockdown (Ctrl versus KD; maize), control versus 1,25 (10 nM, 6 h) (Ctrl versus 1,25; grey) or hnRNPC1/C2
knockdown vs 1,25(OH)2D combined with hnRNPC1/C2 knockdown (KD versus 1,25+KD; blue). (B) Control versus hnRNPC1/C2 knockdown (Ctrl
versus KD, maize) or combined 1,25(OH)2D and hnRNPC1/C2 knockdown (Ctrl versus 1,25+KD, green). (C) Up- and down-regulated differentially ex-
pressed genes: (left) Control versus 1,25(OH)2D (Ctrl versus 1,25) or hnRNPC1/C2 knockdown versus 1,25(OH)2D combined hnRNPC1/C2 knockdown
(KD versus 1,25+KD); (right) Control versus hnRNPC1/C2 knockdown (Ctrl versus KD). (D) Weighted Venn diagrams depicting overlap of differen-
tially expressed genes between Ctrl versus 1,25(OH)2D and KD versus 1,25(OH)2D and hnRNPC1/C2 knockdown. Numbers of differentially expressed
genes are shown within each segment. Heatmaps show patterns of down-regulated (blue) differentially expressed genes (upper heatmaps) and up-regulated
(red) differentially expressed genes (lower heatmaps) for each treatment/knockdown comparison group and the overlapping differentially expressed genes
common to those comparisons. * includes CYP24A1.
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Figure 6. Effect of 1,25(OH)2D and hnRNPC1/C2 knockdown on alternative splicing. (A) Five major types of alternative splicing patterns examined: SE,
Skipped Exon; MXE, Mutually Exclusive Exon; A5SS, Alternative 5′ Splice Site; A3SS, Alternative 3′ Splice Site; RI, Retained Intron. (B) Summary of
the different differentially expressed genes for each type of alternative splicing event identified by RNA-seq data in MG63 cells with various combinations
of no treatment (Ctrl), 1,25(OH)2D (10 nM 1,25, 6 h) exposure and/or hnRNPC1/C2 knockdown (KD). Run fromMATS3.0.8 with significant events at
FDR < 0.05, |PSI| ≥ 0.05. * includes CYP24A1.
Figure 7. Overlap of differentially expressed genes and differentially spliced genes. Venn diagrams depicting overlap of DEG and DSG induced by:
(A) hnRNPC1/C2 knockdown (Ctrl versus KD); (B) 1,25(OH)2D exposure (Ctrl versus 1,25; (10 nM 1,25, 6 h); (C) hnRNPC1/C2 knockdown alone
(KD) compared to 1,25(OH)2D exposure combined with hnRNPC1/C2 knockdown (KD versus 1,25+KD); (D) 1,25(OH)2D-treated cells compared
to 1,25(OH)2D treatment combined with hnRNPC1/C2 knockdown ((1,25 versus 1,25+KD); and (E) combination of 1,25(OH)2D treatment and
hnRNPC1/C2 knockdown relative to control cells (Ctrl versus 1,25+KD). Absolute numbers of DEG and DSG shown within each segment.
DISCUSSION
The over-arching aim of the current study was to investi-
gate a potential link between the established RNA splic-
ing effects of hnRNPC1/C2 and its alternative role in tran-
scriptional regulation as a DNA-binding protein. In par-
ticular we postulated that effects of the active form of vi-
tamin D, 1,25(OH)2D, on gene expression may involve co-
ordination of transcriptional regulation and RNA splic-
ing, with hnRNPC1/C2 linking these two effects. Knock-
down of hnRNPC1/C2 has been used previously to show
how hnRNPC1/C2 acts as a splicing enhancer by enforcing
exon inclusion and preventing exon skipping (8). In HeLa
cells hnRNPC1/C2 competes with the core splicing factor
U2 auxillary factor 65 (U2AF65) to prevent the introduc-
tion of cryptic splice sites (27). To date, studies of DNA
binding of hnRNPC1/C2 and associated transcriptional
effects have focused on over-expression of hnRNPC1/C2
(20). The current study therefore utilized siRNA knock-
down of hnRNPC1/C2 to assess both the transcriptional
and splicing impact of hnRNPC1/C2 using both candidate
gene (CYP24A1) and genome-wide strategies.
In mammalian biology, enhanced expression of
CYP24A1 is the most well recognized and robust re-
sponse in vitro to 1,25(OH)2D exposure (35). In MG63
osteoblastic cells this effect (Figure 1), was associated
with binding of hnRNPC1/C2 to both DNA and RNA
616 Nucleic Acids Research, 2017, Vol. 45, No. 2
for CYP24A1 (Figure 2). As reported previously (20),
chromatin association of hnRNPC1/C2 is reciprocal
with VDR attesting to its competition with the VDR
for VDRE binding. By contrast, 1,25(OH)2D-enhanced
binding of hnRNPC1/C2 to CYP24A1 pre-mRNA was
independent of VDR, suggesting a complementary but
mechanistically distinct response to 1,25(OH)2D. The
CYP24A1 gene is also characterized by established splice
variants that encode enzymatically inactive alternative
forms of the 24-hydroxylase protein (21,22). Expression
of the heme-binding domain-deficient CYP24A1 variant
2 in vehicle-treated MG63 cells was potently induced by
hnRNPC1/C2 knockdown, indicating a significant shift
toward exon-skipping in these cells under these conditions.
This effect was increased further when 1,25(OH)2D was
present to drive transcription of CYP24A1. These data
underline the potential role of hnRNPC1/C2 in coor-
dinating regulation of both transcription and splicing
of the CYP24A1 gene. The data also highlight different
functional responses to knockdown of hnRNPC1/C2
relative to previously reported studies of hnRNPC1/C2
over-expression where the predominant effect was suppres-
sion of 1,25(OH)2D-mediated transcription of CYP24A1
(20).
Genome-wide mRNA expression studies for hnRNPs
have been limited, especially under conditions of tar-
geted provocation (36). As a consequence, the goal of
work presented here was to determine if the concerted ac-
tions of hnRNPC1/C2 and 1,25(OH)2D to alter VDR-
VDRE-directed expression and alternative splicing of the
CYP24A1 gene are reflected in other gene products in the
MG63 human osteoblast-like transcriptome. The number
of differentially expressed genes associated with knock-
down of hnRNPC1/C2 in MG63 cells (3500) was simi-
lar to the number of differentially spliced genes (3921),
underlining the importance of hnRNPC1/C2 beyond its
traditional roles in RNA processing and transport. These
data also confirmed observations in Figure 3 showing in-
duction of CYP24A1 by 1,25(OH)2D, and suppression of
CYP24A1 with hnRNPC1/C2 knockdown. Even though
hnRNPC1/C2 plays a role in lowering the baseline expres-
sion of CYP24A1, 1,25(OH)2D was still able to induce ex-
pression of CYP24A1 in the presence of hnRNPC1/C2
knockdown (Figures 3 and 5). This indicates that while
hnRNPC1/C2 is not essential for 1,25(OH)2D-induced
transcription of this gene, it is able to modulate this re-
sponse.
Further, genome-wide analysis of differentially expressed
genes showed that the combinatorial actions of 1,25(OH)2D
and altered hnRNPC1/C2 expression are not restricted to
CYP24A1. Genome-wide strategies have been used to char-
acterize chromatin-binding of 1,25(OH)2D and associated
effects on gene expression (37). The number of differen-
tially expressed genes identified following treatment with
1,25(OH)2D (324) is similar to previousDNAarray analysis
of primary cultures of human osteoblasts (336) (38). That
being said, the impact of hnRNPC1/C2 on 1,25(OH)2D-
induced differentially expressed genes is complicated by sev-
eral factors. First is the strong effect of hnRNPC1/C2 on
overall gene expression (Figure 5A and B). Second is the
fact that knockdown of hnRNPC1/C2 affected both up-
and down-regulation of gene expression by 1,25(OH)2D
(Figure 5D). Third is the observation that the impact of
hnRNPC1/C2 knockdown on 1,25(OH)2D-induced gene
expression was not universal, as many differentially ex-
pressed genes specifically induced by 1,25(OH)2D were un-
affected by hnRNPC1/C2 knockdown (Figure 5A). Never-
theless, the facts that (i) combined hnRNPC1/C2 knock-
down and exposure to 1,25(OH)2D resulted in 912 differ-
entially expressed genes that were distinct from those dif-
ferentially expressedwith hnRNPC1/C2 knockdown alone,
and (ii) 87 differentially expressed genes were only induced
by 1,25(OH)2D under conditions of hnRNPC1/C2 knock-
down (Figure 5B and Supplementary Data S3) endorses a
role for hnRNPC1/C2 in the normal regulation of gene ex-
pression by 1,25(OH)2D.
Previous studies have characterized transcriptome bind-
ing patterns of hnRNPs (39) and transcriptome-wide
changes in alternative splicing (27). Data presented here
showing genome-wide changes in differentially spliced
genes after hnRNPC1/C2 knockdown are consistent with
its role in maintaining splicing fidelity (27,40). In the ab-
sence or presence of 1,25(OH)2D the majority of differen-
tially spliced genes associated with hnRNPC1/C2 knock-
down were skipped exons, endorsing the previously de-
scribed role of hnRNPC1/C2 in preventing this form of al-
ternative splicing (8). However, despite well documented ac-
tions on the transcriptome (41), exposure to 1,25(OH)2D
alone had minimal effects on alternative splicing of RNA
(Figure 6), not-withstanding the observations in Figure
4 showing enhanced expression of the exon 10-skipped
CYP24A1-variant 2 in 1,25(OH)2D-treated cells. This may
in part reflect the more stringent statistical analysis based
on FDR; analysis of alternative splicing based on P-values
showed 139 skipped exons in 1,25(OH)2D-treated cells, in-
cluding skipping of exon 10 of CYP24A1 (data not shown).
RNA-seq measures steady-state mRNA levels. The al-
tered mRNA levels of certain differentially spliced genes
may result from the degradation of specific, alternatively
spliced transcripts by the mRNA nonsense-mediated de-
cay pathway. A second (and not mutually exclusive) ex-
planation is that some of the transcriptional actions of
hnRNPC1/C2 are linked to its effects on RNA splicing.
The latter hypothesis was supported by data from mini-
gene constructs, which showed that a CYP24A1 exon 10
skipping event was less likely to occur in the presence of
a functional VDRE (Figure 4). Transcriptomic data also
showed overlap between the transcription and splicing ef-
fects of hnRNPC1/C2 (Figure 7D). However, this only oc-
curred in 20%of differentially spliced genes for 1,25(OH)2D
versus combined 1,25(OH)2D and hnRNPC1/C2 knock-
down (Figure 7D), indicating that any putative link between
gene expression and splicing effects of hnRNPC1/C2 is not
universal. Likewise, although comparison of hnRNPC1/C2
knockdown with knockdown plus 1,25(OH)2D resulted in
355 differentially expressed genes, only one of these was also
alternatively spliced under the same conditions. These data
suggest that although hnRNPC1/C2 plays a dual role in
regulating transcription and RNA splicing, these actions
are not necessarily linked directly through 1,25(OH)2D-
VDR chromatin signaling. However, it is important to rec-
ognize that hnRNPC1/C2 also plays a role in the export of
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transcripts from the nucleus. Specifically hnRNPC1/C2 de-
lineates the length of transcripts for export as either mRNA
(>200–300 nucleotides) or snRNA (<200–300 nucleotides)
by competing for RNA binding with RNA adapter pro-
teins (42). It is therefore possible that hnRNPC1/C2 links
1,25(OH)2D-VDR-driven transcription with RNA export
rather than splicing. In future studies, it will be important
to assess the impact of hnRNPC1/C2 on the size and sub-
cellular localization of transcripts in bone cells induced by
active vitamin D metabolites.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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